Table 1

Cases and case series highlighting the use of ICB in patients with underlying ILD

Study	Case	Age (years)	Histology	Pre-existing ILD	Pneumonitis
Kanai et al,8 Thorac Cancer (2018)	1	72	Squamous	UIP	AIP
	2	76	Adenocarcinoma	NSIP	AIP
	3	72	Adenocarcinoma	NSIP	COP
	4	69	Squamous	UIP	COP
	5	62	Squamous	UIP	AIP
	6	74	Adenocarcinoma	NSIP	COP
	7	55	Adenocarcinoma	NSIP	NSIP
	8	65	Squamous	NSIP	COP
Fujimoto et al,9 Lung Cancer (2017)	1	71	NSCLC-NOS	UIP	None
	2	73	NSCLC-NOS	Inconsistent UIP	None
	3	69	Adenocarcinoma	UIP	None
	4	80	Adenocarincoma	UIP	None
	5	81	Adenocarcinoma	UIP	None
	6	64	Squamous	UIP	None
Khunger et al,10 Journal of Thoracic Oncology (2017)	1	67	Squamous	Combined IPF	None

All patients were males
AIP, acute interstitial pneumonia; COP, cryptogenic organizing pneumonia; ICB, immune checkpoint blockade; ILD, interstitial lung disease; IPF, interstitial pulmonary fibrosis; NOS, not-otherwise specified; NSCLC, non-small-cell lung cancer; NSIP, non-specific interstitial pneumonia; UIP, usual interstitial pneumonia.